OPTIMAL METHOD OF TREATMENT OF ARTERIAL HYPERTENSION COMBINED WITH DYSPLASIA OF CONNECTIVE TISSUE
DOI:
https://doi.org/10.11603/1811-2471.2018.v0.i3.9276Keywords:
arterial hypertension, connective tissue dysplasia, ramipril/amlodipine, 2-ethyl-6-methyl-3-hydroxypyridine succinateAbstract
Arterial hypertension (AН) is one of the most aggressive risk factors for the formation and progression of the pathology of the cardiovascular system (CVS) with lesions of the target organs and the development of associated diseases: coronary heart disease, acute and chronic cerebral pathology, systemic atherosclerosis, lesion of the glomerular kidney system with the development of nephropathy and renal failure.
The aim of the study – to improve the efficiency of treatment of patients with hypertension combined with connective tissue dysplasia (СTD) based on the study of clinical course, the severity of external and internal phenotypic signs of CTD, inflammation activity, blood clotting systems using the combination of ACE inhibitors and CCB using metabolic therapy in a complex treatment.
Material and Methods. We examined 57 patients (24 women and 33 men) at the AH II – III stages with manifestations of СTD. The patients were divided into 3 groups: the group I (main) – 35 patients who, in addition to the baseline therapy, received 2-ethyl-6-methyl-3-hydroxypyridine succinate (мexicor); group II (comparison) – 22 patients who received basic therapy according to the clinical protocol; group ІІІ – 20 practically healthy persons. In the baseline therapy among antihypertensive agents was a combination of ramipril/amlodipine (hartyl-AM) with titration of dose depending on baseline blood pressure levels, daily blood pressure monitoring (DBPM). Patient examination was carried out in accordance with the protocol developed by us: objective review, laboratory tests (coagulogram: prothrombin time (PT), prothrombin index (PI) and total fibrinogen (ТF), determination of C-reactive protein (CRP)), instrumental examination methods (ECG, echocardiography, DMAP, ultrasound examination of the internal organs and vessels of the lower extremities, ultrasound duplex examination of the sleep and vertebral arteries, X-ray examination of the bone and articular system), consultation of an ophthalmologist, a neuropathologist, a traumatologist, a dentist.
Results. As a result of the research conducted in patients with hypertension II–III stage diagnosis of CTD of varying degrees of severity. In the group I of patients with CTD of average severity 30 (85.7 %), in the group II – in 20 (90.9 %), severe severity was observed – in 5 (14.3 %) and 2 (9.1%) patients respectively.
The results of the study showed that up to 10 days of treatment in the main group, the average daily SAT and DAT decreased by 15.6 % and 17.5 % respectively, and up to 30 days – by 25.2 % and 26.4 %. After application of ramipril/amlodipine and 2-ethyl-6-methyl-3-hydroxypyridine succinate in the complex treatment of patients with hypertension associated with CTD, the CRP level decreased by 42.79 % for 10 days of treatment (p<0.01) and 2-fold after 30 days of observation. The level of PI for 10 days has significantly changed – (85.52±4.93) (p <0.05), after 30 days of inpatient treatment – (82.39±5.13) (p <0.05).
Conclusions. The use of ramipril/amlodipine and 2-ethyl-6-methyl-3-hydroxypyridine succinate in the complex treatment of patients with hypertension combined with СТD improves the clinical course of the disease, reduces the incidence of relapses of hypertensive crises, reduces the number of complications, reduces the timing of stabilization of blood pressure, promotes normalization CRP and blood coagulation indexes.
References
(2017). Derzhavna sluzhba statystyky Ukrainy: Demohrafichna ta sotsialna statystyka. Okhorona zdorovia. Zakhvoriuvanist naselennia (za danymy Ministerstva okhorony zdorovia) [The State Statistics Service of Ukraine: Demographic and Social Statistics. Healthcare The incidence of the population (according to the Ministry of Health). Retrieved from: http://www.ukrstat.gov.ua [in Ukrainian].
Kovalenko, V.M., & Kornatskyi, V.M. (Eds.). (2017). Problema zdorovia i tryvalosti zhyttia v suchasnykh umovah [The problem of health and life expectancy in modern conditions]. Kyiv [in Ukrainian].
Koval, S.M., Bozhko, V.V., & Penkova, M.Yu. (2010). Hiperurikemiia ta sumarnyi ryzyk uskladnen u patsiientiv z hipertonichnoiu khvoroboiu [Hyperuricemia and total risk of complications in hypertensive patients (according to clinical data)]. Ukrainskyi revmatolohichnyi zhurnal – Ukrainian Rheumatological Journal, 4, 42-48 [in Ukrainian].
Zaremba, Ye.H., Rak, N.O., & Hrib, N.V. (2017). Zviazok mizh nedyferentsiiovanoiu dysplaziieiu spoluchnoi tkanyny ta arterialnoiu hipertenziieiu [Relationship between undifferentiated connective tissue dysplasia and arterial hypertension]. Zdorovia i suspilstvo – Health and Society, 1-2, 139-140 [in Ukrainian].
Nechayeva, G.I., Yakovlev, V.M., & Konev, V.P. (2008). Displaziya soyedinitelnoy tkani: osnovnye klinicheskie sindromy, formulirovka diagnoza, lechenie [Dysplasia of the connective tissue: the main clinical syndromes, the formulation of the diagnosis, treatment]. Lechashchiy vrach – Attending Physician, 2, 22-25 [in Russian].
Kadurina, T.I. (2000). Nasledstvennye kollagenopatii: klinika, diagnostika, lechenie, dispanserizatsiya [Hereditary collagenopathies: clinic, diagnosis, treatment, clinical examination]. Saint-Petersburg: Nevskiy dialekt [in Russian].
Mitchenko, O.I., Kaspruk, H.B., & Romanov, V.Yu. (2010). Hipertrofiia miokarda livoho shlunochka u khvorykh z arterialnoiu hipertenziieiu na tli metabolichnoho syndromu, zviazok iz faktoramy sertsevo-sudynnoho ryzyku [Left ventricular myocardial hypertrophy in patients with arterial hypertension against metabolic syndrome, association with cardiovascular risk factors]. Ukr. kardiol. Zhurn. – Ukrainian Cardiologic Journal, 1, 22-27 [in Ukrainian].
Sirenko, Yu.M. (2010). Hipertrofiia livoho shlunochka: metody otsinky, mozhlyvosti rehresuvannia [Left ventricular hypertrophy: evaluation methods, regression posibilities]. Arterialnaya gipertenziya – Arterial Hypertension, 4 (12), 82-90 [in Ukrainian].
Sirenko, Yu.M. (2010). Arterialna hipertenziia ta suputnia patolohiia [Arterial hypertension and concomitant pathology]. Donetsk: Vydavets Zaslavskyi O.Yu. [in Ukrainian].
Sydorchuk, L.P., & Amosova, K.M. (2010). Vplyv tryvaloho farmakohenetychnoho determinovanoho likuvannia na pokaznyky ehokardiohrafii ta heometrychni modeli miokarda livoho shlunochka u khvorykh z arterialnoiu hipertenziieiu [Influence of long-term pharmacogenic deterministic treatment on echocardiography and geometric models of left ventricular myocardium in patients with arterial hypertension]. Ukr. kardiol. Zhurn – Ukrainian Cardiologic Journal, 5, 30-41 [in Ukrainian].
Akimov, A.G., & Polumiskov, V.Yu. (2005). Perspektivy primeneniya miokardialnykh tsitoprotektorov v kardiologicheskoy praktike [Prospects for the use of myocardial cytoprotectors in cardiological practice]. Terra Medica Nova, 3, 10-15 [in Russian].
Parkhomenko, A.N. (2001). Zhiznesposobnyy miokard i kardiotsitoprotektsiya: vozmozhnosti metabolicheskoy terapii pri ostroy i khronicheskoy formakh ishemicheskoy bolezni serdtsa [Viable myocardium and cardiocytoprotection: the possibilities of metabolic therapy in acute and chronic forms of coronary heart disease]. Ukr. med. Chasopys – Ukrainian Medical Journal, 3 (23), 5-11 [in Russian].
Liem, D., Honda, H., & Zhang, J. (2007). Past and present course of cardioprotection against ischemia/reperfusion injury. J. Appl. Physiol., 103, 2129-2136.
